Humana is a leading health insurance company that provides a wide range of health and wellness solutions to individuals, families, and employers. The organization offers Medicare Advantage plans, Medicaid services, and individual health insurance policies, focusing on enhancing the health and well-being of its members. Additionally, Humana invests in technology and innovative care management services, aiming to improve healthcare delivery and patient outcomes. The company is dedicated to integrating medical and wellness services to create a comprehensive approach to health management for its customers. Read More
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Health insurance company Humana (NYSE:HUM) announced better-than-expected revenue in Q2 CY2025, with sales up 9.6% year on year to $32.39 billion. The company’s full-year revenue guidance of $128 billion at the midpoint came in 1% above analysts’ estimates. Its GAAP profit of $4.51 per share was 24% below analysts’ consensus estimates.
Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended June 30, 2025 (2Q25) versus the quarter ended June 30, 2024 (2Q24) and for the six months ended June 30, 2025 (YTD 2025) versus the six months ended June 30, 2024 (YTD 2024) as noted in the tables below.
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO)
fell 20.2% in the morning session after the company reported second-quarter results that included a significant cut to its full-year financial guidance, sparking a selloff.
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN)
jumped 7.8% in the morning session after the company reported strong second-quarter 2025 financial results and raised its full-year guidance. The life sciences company announced that its revenue climbed 15% year-over-year to $182 million, driven by growth across all its franchises and geographies. Profitability also saw a substantial increase, with net income rising to $14.87 million from $5.71 million in the same quarter last year. A key indicator of future performance, company orders, grew by over 20%. Buoyed by these strong results, Repligen lifted its full-year 2025 revenue forecast to a range of $715 million to $735 million.
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN)
fell 3.8% in the afternoon session after weakness in the healthcare sector became pronounced following a poor sales report from a key competitor. The negative sentiment was partly fueled by health insurance giant UnitedHealth Group, which reported a miss on its second-quarter earnings and issued a profit warning, casting a pall over the entire sector. More directly, NeoGenomics, a company also operating in the cancer diagnostics space, reported that it had missed its second-quarter sales targets. This news, which sent NeoGenomics' stock down significantly, suggested a potentially more challenging market environment for companies involved in oncology diagnostics, a core business for Myriad Genetics.
Shares of life sciences company Revvity (NYSE:RVTY)
fell 7.6% in the afternoon session after the company lowered its full-year profit forecast, which overshadowed its second-quarter earnings and revenue beat. Despite reporting second-quarter revenue of $720 million and an adjusted earnings per share (EPS) of $1.18, both of which surpassed analyst expectations, investors focused on the weaker outlook. Revvity trimmed its full-year adjusted EPS guidance to a range of $4.85 to $4.95. This revision was driven by multiple headwinds, including a double-digit decline in its diagnostics revenue from China, a key international market. The company also faced shrinking profitability, as both its adjusted operating and gross margins fell compared to the previous year. Management also pointed to potential costs related to tariffs.
Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL)
fell 3.7% in the morning session after the company extended a recent losing streak amid investor anxiety ahead of its second-quarter earnings announcement.
Shares of health coverage company Centene (NYSE:CNC)
jumped 5.9% in the afternoon session after the company reported second-quarter results that missed earnings estimates, but the stock rallied as investors looked past the disappointment as sales came in ahead of expectations.
Shares of medical technology company Integer Holdings (NYSE:ITGR)
fell 8.3% in the afternoon session after the company reported second-quarter results that featured a slight miss on a key profitability metric, which overshadowed a revenue beat and raised profit guidance.
Shares of healthcare products company West Pharmaceutical Services (NYSE:WST)
jumped 22.9% in the afternoon session after the company reported strong second-quarter 2025 financial results and raised its full-year outlook.
A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally. The positive sentiment swept across markets after it was announced the U.S. and Japan had reached a new trade deal. The agreement included a 15% tariff on Japanese goods imported into the U.S. and a commitment from Japan to invest $550 billion in the U.S. and open its markets to American cars and agricultural products. This development boosted investor confidence and contributed to a widespread rally, lifting stocks across many sectors. The Dow Jones Industrial Average and the S&P 500 both posted gains, creating a favorable environment that likely benefited individual stocks.
Shares of life sciences company Thermo Fisher (NYSE:TMO)
jumped 12.3% in the afternoon session after the company reported second-quarter earnings and revenue that surpassed Wall Street estimates and raised its full-year financial guidance. The company posted adjusted earnings per share (EPS) of $5.36 on revenue of $10.85 billion. These results topped the average analyst estimates, which had projected an EPS of $5.22 on revenue of $10.65 billion. EPS is a widely used metric of a company's profitability. Following the strong quarterly performance, Thermo Fisher lifted its outlook for the full year. The company now expected 2025 revenue to be between $43.6 billion and $44.2 billion, raising the lower end of its previous forecast. It also increased its adjusted EPS guidance to a range of $22.22 to $22.84. The better-than-expected results were driven by growth in its Life Sciences Solutions and Lab Products & Biopharma Services divisions.
Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 5.7% in the afternoon session after the investment firm Stephens initiated coverage on the life sciences company.
